XSHE
002750
Market cap75mUSD
Apr 03, Last price
1.38CNY
1D
-1.43%
1Q
-30.30%
Jan 2017
-91.58%
IPO
-72.53%
Name
Kunming Longjin Pharmaceutical Co Ltd
Chart & Performance
P/E
—
P/S
6.38
EPS
—
Div Yield, %
—
Shrs. gr., 5y
-0.02%
Rev. gr., 5y
-23.75%
Revenues
87m
-29.56%
Net income
-71m
CFO
-39m
Dividend
May 23, 20180.03 CNY/sh
Earnings
May 21, 2025
Profile
Kunmig Longjin Pharmaceutical Co., Ltd. develops, produces, and sells natural botanicals and chemical freeze-dried powder injections in China. The company offers Chinese, biochemical, chemical, cardio-cerebral vascular, and digestive system medicines; immune system and first aid medications; and vitamins, minerals, and enteral and parenteral nutrition products. It also engages in the industrial hemp plantation business. The company was founded in 1996 and is headquartered in Kunming, China.
Valuation
Title CNY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | 2015‑12 | |
| Income | |||||||||
Revenues | 86,623 -29.56% | 122,966 -82.50% | |||||||
Cost of revenue | 130,822 | 140,085 | |||||||
Unusual Expense (Income) | |||||||||
NOPBT | (44,200) | (17,120) | |||||||
NOPBT Margin | |||||||||
Operating Taxes | 2,020 | 4,799 | |||||||
Tax Rate | |||||||||
NOPAT | (46,220) | (21,919) | |||||||
Net income | (70,941) | ||||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | (670) | ||||||||
BB yield | 0.02% | ||||||||
| Debt | |||||||||
Debt current | 171 | ||||||||
Long-term debt | 1,609 | 1,967 | |||||||
Deferred revenue | 39,492 | 41,501 | |||||||
Other long-term liabilities | 12,298 | ||||||||
Net debt | (332,960) | (402,208) | |||||||
| Cash flow | |||||||||
Cash from operating activities | (39,261) | ||||||||
CAPEX | (15,665) | ||||||||
Cash from investing activities | 56,040 | 115,999 | |||||||
Cash from financing activities | 2,885 | (12,523) | |||||||
FCF | (24,120) | (1,144) | |||||||
| Balance | |||||||||
Cash | 334,149 | 404,347 | |||||||
Long term investments | 420 | ||||||||
Excess cash | 330,238 | 398,199 | |||||||
Stockholders' equity | 490,134 | 604,653 | |||||||
Invested Capital | 251,185 | 251,173 | |||||||
ROIC | |||||||||
ROCE | |||||||||
| EV | |||||||||
Common stock shares outstanding | 400,500 | 400,500 | |||||||
Price | 10.00 -10.15% | 11.13 -31.00% | |||||||
Market cap | 4,005,000 -10.15% | 4,457,565 -31.00% | |||||||
EV | 3,701,279 | 4,077,092 | |||||||
EBITDA | (13,611) | 12,667 | |||||||
EV/EBITDA | 321.88 | ||||||||
Interest | 13,182 | ||||||||
Interest/NOPBT | |||||||||